Solid Tumor, Unspecified, Adult Clinical Trial
Official title:
68Ga-FAPI-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation
Phase II, open label, single arm, single center, prospective diagnostic trial to evaluate the Fibroblast Activating Protein (FAP) positivity in patients with solid tumors
The growth and spread of the tumor is determined not only by the tumor cells but also by the non-malignant constituents of the malignant lesion, which contributes to what is commonly referred to as the "tumor microenvironment". In particular, a subpopulation of fibroblasts called cancer-associated fibroblasts are involved in tumor growth, migration and progression. Therefore, these cells represent an attractive target for both diagnosis and anticancer therapy. A distinctive feature of cancer-associated fibroblasts is the expression of the fibroblast activating protein, a type II membrane-bound glycoprotein. Fibroblast Activating Protein plays a role in normal developmental processes during embryogenesis and in tissues modeling. The presence of Fibroblast Activating Protein in cancer-associated fibroblasts in many solid tumors and the fact that overexpression is associated with a worse prognosis in cancer patients has led to the hypothesis that Fibroblast Activating Protein plays a fundamental role in the development of cancer, in the migration of cancer cells, and in the spread of cancer. Therefore, the targeting of this enzyme for imaging and endo-radiotherapy can be seen as a promising strategy for detecting and treating malignant tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03628677 -
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05723640 -
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
|
Phase 1 | |
| Completed |
NCT04976803 -
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
|
||
| Recruiting |
NCT04932525 -
Gustave Roussy Cancer Profiling
|
Phase 1 | |
| Recruiting |
NCT04643418 -
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04443088 -
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04942717 -
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
|
||
| Recruiting |
NCT04169321 -
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
|
Phase 1 | |
| Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
| Completed |
NCT03318445 -
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
|
Phase 1 | |
| Recruiting |
NCT04537936 -
Psychotherapy Intervention for Latinos With Adv Cancer
|
N/A | |
| Completed |
NCT04252339 -
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04577963 -
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04015609 -
Psychotherapy Intervention for Latinos With Advanced Cancer
|
N/A | |
| Available |
NCT04100694 -
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
|